Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuCarbo: Pluvicto Plus Carboplatin in mCRPC
NCT06303713Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- DNA Intercalators/Alkylators, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of carboplatin and lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose or Recommended Phase 2 Dose at 6 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
carboplatinlutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06303713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303713.